Cboe BZX
11:08:34 2024-04-23 am EDT
5-day change
1st Jan Change
3.1
USD
+5.44%
+15.57%
+129.85%
Trevi Therapeutics, Inc. announced that it has received $11.819892 million in funding
On October 20, 2021, Trevi Therapeutics, Inc. closed the transaction. The transaction included participation from a single investor.
Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024
Mar. 20
Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 20
CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 20
CI
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio? for Chronic Cough in Idiopathic Pulmonary Fibrosis
Dec. 05
CI
Transcript : Trevi Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Nov. 09
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio?? for Refractory Chronic Cough
Nov. 02
CI
Trevi Therapeutics, Inc. Announces Results from Phase 2b/3 Prism Open-Label Extension Study of Haduvio in Prurigo Nodularis
23-10-13
CI
Transcript : Trevi Therapeutics, Inc., Q2 2023 Earnings Call, Aug 10, 2023
23-08-10
Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Trevi Therapeutics Files $200 Million Mixed Shelf
23-06-30
MT
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell Small Cap Comp Value Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000 Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell 3000E Growth Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000E Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell Small Cap Completeness Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000 Value Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 2500 Value Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 2500 Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 2000 Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell Microcap Value Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000E Value Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 2000 Value Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 2000 Dynamic Index
23-06-23
CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell Microcap Growth Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.
More about the company
Last Close Price
2.94
USD
Average target price
7.4
USD
Spread / Average Target
+151.70%
Consensus
1st Jan change
Capi.
+129.85% 203M -0.10% 103B +3.27% 96.73B +1.92% 21.31B -15.49% 21.21B -6.82% 18.79B -41.41% 16.37B -22.01% 13.68B +6.02% 13.44B +23.87% 10.98B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
TREVI THERAPEUTICS, INC. 
